bluebird bio, Inc. (0HOH.L)
USD 8.02
(1.01%)
USD 8.02
(1.01%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 240.23 Million USD | -12.86% |
| 2022 | 275.67 Million USD | -47.98% |
| 2021 | 529.91 Million USD | -39.43% |
| 2020 | 874.85 Million USD | 2.47% |
| 2019 | 853.77 Million USD | 37.1% |
| 2018 | 622.71 Million USD | 69.87% |
| 2017 | 366.59 Million USD | 35.83% |
| 2016 | 269.89 Million USD | 49.74% |
| 2015 | 180.24 Million USD | 110.08% |
| 2014 | 85.8 Million USD | 90.13% |
| 2013 | 45.12 Million USD | 87.6% |
| 2012 | 24.05 Million USD | 50.12% |
| 2011 | 16.02 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 71.4 Million USD | -11.71% |
| 2024 Q2 | 75.54 Million USD | 5.81% |
| 2023 Q3 | 86.16 Million USD | 4.29% |
| 2023 Q2 | 82.62 Million USD | -1.05% |
| 2023 Q1 | 83.49 Million USD | 428.8% |
| 2023 Q4 | 80.87 Million USD | -6.14% |
| 2023 FY | 240.23 Million USD | -12.86% |
| 2022 Q3 | 86.55 Million USD | -13.91% |
| 2022 FY | 275.67 Million USD | -47.98% |
| 2022 Q2 | 100.53 Million USD | -11.8% |
| 2022 Q1 | 113.98 Million USD | -14.03% |
| 2022 Q4 | -25.39 Million USD | -129.34% |
| 2021 Q3 | 199.7 Million USD | -10.4% |
| 2021 Q4 | 132.59 Million USD | -33.61% |
| 2021 FY | 529.91 Million USD | -39.43% |
| 2021 Q2 | 222.89 Million USD | -7.65% |
| 2021 Q1 | 241.35 Million USD | 12.75% |
| 2020 Q3 | 208.47 Million USD | -7.32% |
| 2020 Q1 | 227.37 Million USD | -4.48% |
| 2020 Q2 | 224.93 Million USD | -1.07% |
| 2020 FY | 874.85 Million USD | 2.47% |
| 2020 Q4 | 214.06 Million USD | 2.68% |
| 2019 FY | 853.77 Million USD | 37.1% |
| 2019 Q1 | 182.91 Million USD | 5.59% |
| 2019 Q2 | 215.17 Million USD | 17.63% |
| 2019 Q4 | 238.02 Million USD | 9.35% |
| 2019 Q3 | 217.66 Million USD | 1.16% |
| 2018 FY | 622.71 Million USD | 69.87% |
| 2018 Q4 | 173.23 Million USD | 7.42% |
| 2018 Q3 | 161.27 Million USD | 3.26% |
| 2018 Q2 | 156.18 Million USD | 18.29% |
| 2018 Q1 | 132.03 Million USD | 8.53% |
| 2017 Q3 | 84.52 Million USD | -1.15% |
| 2017 FY | 366.59 Million USD | 35.83% |
| 2017 Q2 | 85.5 Million USD | 13.54% |
| 2017 Q1 | 75.31 Million USD | 2.73% |
| 2017 Q4 | 121.66 Million USD | 43.93% |
| 2016 Q2 | 60.12 Million USD | 3.9% |
| 2016 Q1 | 57.86 Million USD | 15.49% |
| 2016 Q3 | 78.59 Million USD | 30.72% |
| 2016 Q4 | 73.31 Million USD | -6.72% |
| 2016 FY | 269.89 Million USD | 49.74% |
| 2015 Q1 | 31.05 Million USD | 20.21% |
| 2015 FY | 180.24 Million USD | 110.08% |
| 2015 Q2 | 54.99 Million USD | 77.07% |
| 2015 Q3 | 44.09 Million USD | -19.81% |
| 2015 Q4 | 50.1 Million USD | 13.61% |
| 2014 FY | 85.8 Million USD | 90.13% |
| 2014 Q3 | 23.29 Million USD | 18.45% |
| 2014 Q4 | 25.83 Million USD | 10.89% |
| 2014 Q1 | 17 Million USD | 17.67% |
| 2014 Q2 | 19.66 Million USD | 15.68% |
| 2013 Q2 | 10.52 Million USD | 38.38% |
| 2013 Q4 | 14.45 Million USD | 15.21% |
| 2013 FY | 45.12 Million USD | 87.6% |
| 2013 Q1 | 7.6 Million USD | -15.85% |
| 2013 Q3 | 12.54 Million USD | 19.13% |
| 2012 Q3 | 5.1 Million USD | 9.05% |
| 2012 Q2 | 4.68 Million USD | -10.27% |
| 2012 Q1 | 5.22 Million USD | 0.0% |
| 2012 Q4 | 9.04 Million USD | 76.96% |
| 2012 FY | 24.05 Million USD | 50.12% |
| 2011 FY | 16.02 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 86.243% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -1878.684% |
| Myriad Genetics, Inc. | 600.1 Million USD | 59.968% |
| Evolus, Inc. | 189.75 Million USD | -26.598% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 69.185% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 88.642% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 41.236% |
| uniQure N.V. | 285.08 Million USD | 15.733% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -330.863% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 12.862% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -395.303% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 86.654% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 34.828% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 43.825% |
| Dynavax Technologies Corporation | 219.14 Million USD | -9.622% |
| Editas Medicine, Inc. | 247.3 Million USD | 2.86% |
| FibroGen, Inc. | 398.11 Million USD | 39.657% |
| Geron Corporation | 70.44 Million USD | -241.04% |
| Blueprint Medicines Corporation | 722.86 Million USD | 66.767% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 88.298% |
| Illumina, Inc. | 3.81 Billion USD | 93.7% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 46.733% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -513.572% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 84.953% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -68.628% |
| Adicet Bio, Inc. | 152.03 Million USD | -58.008% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 82.346% |
| Insmed Incorporated | 949.26 Million USD | 74.693% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 56.445% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 77.948% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -437.829% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 54.588% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 99.408% |
| Waters Corporation | 943.51 Million USD | 74.539% |
| Zoetis Inc. | 2.76 Billion USD | 91.312% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 97.657% |
| Biogen Inc. | 5.2 Billion USD | 95.385% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -5.052% |
| Nektar Therapeutics | 190.9 Million USD | -25.84% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -138.262% |
| Perrigo Company plc | 1.52 Billion USD | 84.283% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 49.569% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -99.103% |
| Verastem, Inc. | 92.08 Million USD | -160.884% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 94.969% |
| Imunon, Inc. | 21.03 Million USD | -1042.307% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -1627.09% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 11.646% |
| Homology Medicines, Inc. | 9.87 Million USD | -2332.729% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 91.467% |
| OPKO Health, Inc. | 574.68 Million USD | 58.198% |
| Exelixis, Inc. | 1.58 Billion USD | 84.86% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 19.74% |
| TG Therapeutics, Inc. | 198.47 Million USD | -21.039% |
| Incyte Corporation | 1.19 Billion USD | 79.821% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 76.989% |